The Lancet Infectious Diseases in conversation with

The Lancet Group
undefined
Oct 23, 2025 • 26min

In Conversation with Steven Tong and Joshua Davis on adaptive platform trials

Professors Steven Tong and Joshua Davis, experts in infectious diseases and design of clinical trials, delve into adaptive platform trials. They discuss the pros and cons, emphasizing efficiency and the risk of complexity. The duo explains why these trials surged during COVID-19 and the variety of adaptations possible. They share tips for successful implementation, including the importance of experienced teams and community engagement. Finally, they highlight groundbreaking upcoming trials that could revolutionize infectious disease treatment.
undefined
Sep 16, 2025 • 29min

Anna Odone, Jesus Rodriguez-Manzano, and Alex Howard on artificial intelligence and infectious diseases

Professor Ana Odone, Dr Jesus Rodriguez-Manzano, and Dr Alex Howard discuss their new Series of papers on artificial intelligence and infectious diseases intended to support the infectious diseases community in understanding this evolving landscape and in actively shaping artificial intelligence integration into practice.Read the full Series here:https://www.thelancet.com/series-do/artificial-intelligence-and-infectious-diseases?dgcid=buzzsprout_icw_podcast_laninfaiandid25_laninfContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
undefined
Aug 11, 2025 • 18min

Catherine Liu and Joshua Hill on prevention and management of infections in people who are immunocompromised

Drs Catherine Liu and Joshua Hill of the Fred Hutchinson Cancer Center discuss their new Series of papers on the prevention and management of infections in people who are immunocompromised, with a focus on prevention of infections and diagnostic and antimicrobial stewardship.Read the Series papers:https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(25)00345-7/fulltext?dgcid=buzzsprout_icw_podcast_August_25_laninfhttps://www.thelancet.com/journals/laninf/article/PIIS1473-3099(25)00311-1/fulltext?dgcid=buzzsprout_icw_podcast_August_25_laninfRead the linked Comment:https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(25)00355-X/fulltext?dgcid=buzzsprout_icw_podcast_August_25_laninfContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
undefined
Jul 9, 2025 • 30min

Lilian Tina Minja and Norbert Heinrich on TB drug development

Lilian Tina Minja and Norbert Heinrich discuss the SUDUCO and DECODE trials in The Lancet Infectious Diseases on two new promising TB drugs, sutezolid and delpazolid, respectively. They also discuss the wider implications of the findings of these trials for TB drug development and treatment.Read the trials:https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(25)00213-0/fulltext?dgcid=buzzsprout_icw_podcast_July_25_laninfhttps://www.thelancet.com/journals/laninf/article/PIIS1473-3099(25)00289-0/fulltext?dgcid=buzzsprout_icw_podcast_July_25_laninfContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
undefined
Jun 10, 2025 • 15min

Leonardo Basso and Juan Pablo Torres on the NIRSE-CL study of nirsevimab in Chile

Leonardo Basso and Juan Pablo Torres discuss their study in The Lancet Infectious Diseases on the effectiveness and impact of the first season of Chile's national immunisation programme with nirsevimab. They discuss the evidence that led to the design and implementation of the programme, its impact on RSV burden and the Chilean health system, and lessons for other countries in the region and beyond.Read the full article at: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(25)00233-6/fulltext?dgcid=buzzsprout_icw_podcast_10-06-25_laninfContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
undefined
Apr 14, 2025 • 35min

Jan Felix Drexler and Fernando Bozza on Oropouche virus

Jan Felix Drexler, a virology expert from Berlin, and Fernando Bozza, a specialist in infectious diseases from Brazil, delve into the pressing issues surrounding the Oropouche virus. They discuss their recent laboratory-based study on the virus's ecology and its broader implications for arbovirus transmission in Latin America. Key topics include the challenges posed by urbanization, the impact of COVID-19 on mosquito control efforts, and the need for improved diagnostics and healthcare systems. Their insights highlight the urgency for collaborative public health strategies to combat emerging infections.
undefined
Feb 23, 2024 • 19min

Prasad Kulkarni on dengue monoclonal antibodies

Prasad Kulkarni discusses a new Phase I trial in The Lancet Infectious Diseases on a dengue monoclonal antibody also known as VIS513 in healthy adults. In addition, he highlights the wider implications of this for dengue control and drug development.Read the full article:https://www.thelancet.com/journals/laninf/article/ S1473-3099(24)00030-6/fulltext?dgcid=buzzsprout_icw_podcast_generic_laninfContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
undefined
Jan 8, 2024 • 15min

Oriol Mitjà on treatment of early syphilis in adults

Oriol Mitjà discusses a new trial in The Lancet Infectious Diseases on the use of oral linezolid compared with benzathine penicillin G for the treatment of early syphilis in adults. He also highlights what the trial means for treatment of syphilis.Read the full article:https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00683-7/fulltext?dgcid=buzzsprout_icw_podcast_generic_laninfContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
undefined
Nov 10, 2023 • 25min

Sofia Viegas and Stefan Niemann on emerging bedaquiline resistance in Mozambique

Sofia Viegas and Stefan Niemann discuss a new article in The Lancet Infectious Diseases about emerging bedaquiline resistance in Mozambique and its implications for drug resistant tuberculosis and the fight to end tuberculosis.Read the full article:https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00498-X/fulltext?dgcid=buzzsprout_icw_podcast_generic_laninfContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
undefined
Sep 27, 2022 • 17min

Luciano Moreira and Henrik Salje on Wolbachia control of mosquito-borne infections

Luciano Moreira and Henrik Salje discuss a new article in The Lancet Infectious Diseases describing the use of the Wolbachia bacteria to control the spread of mosquito-borne dengue and chikungunya in Rio de Janeiro, Brazil.Read the full article:Estimating the effect of the wMel release programme on the incidence of dengue and chikungunya in Rio de Janeiro, BrazilContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app